30 December 2022
Transense Technologies plc
("Transense" or the "Company")
Total voting rights
Transense Technologies plc, the provider of specialist sensor systems, announces that the issued share capital of the Company at the date of this announcement comprises 16,437,740 ordinary shares of 10 pence ("Ordinary Shares"). The Company holds 604,027 Ordinary Shares in treasury and therefore, the total number of voting rights in the Company is 15,833,713.
The figure of 15,833,713 should be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.
For further information please visit www.transense.com or contact:
| | ||||||
| Notes to Editors:
Transense develops and supplies wireless sensor technology and systems. The Company has three business areas: Transense is a developer of specialist wireless sensor systems used to enable real-time data gathering and monitoring. Products include the patent protected Surface Acoustic Wave (SAW) sensor technology, used to improve equipment power, performance, reliability and efficiency; iTrack, Transense 's Tyre Pressure Monitoring System, licensed to Bridgestone Corporation, the world's largest tyre producer, under a ten-year deal in June 2020; and a range of intelligent tyre monitoring equipment under the Translogik brand. Target sectors include aerospace, electric motors & drives, industrial machinery and performance automotive. The Company 's strategy is to maximise shareholder value through the delivery of sustained revenue growth from all three principal technologies - SAW, iTrack and Translogik probes - through leveraging excellence in innovation, know-how in commercialising technologies, industry partnerships and exposure to global growth markets. Transense is headquartered in Oxfordshire, UK, and was admitted to trading on AIM, a market operated by the London Stock Exchange (AIM: TRT), in 1999. For further information please contact transense@walbrookpr.com or visit www.transense.com.
| |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
